Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Deutsche Bank Brightens Its View On Illumina

Courtesy of Benzinga.

Deutsche Bank Brightens Its View On Illumina

Dan Leonard, Deutsche Bank’s research analyst, upgraded Illumina, Inc. (NASDAQ: ILMN) from Hold to Buy and increased its 12-month price target from $195 to $250.

The analyst is optimistic due to positive newsflow in the clinical markets, which should cause higher enthusiasm about the total addressable market among investors.

He applied 10.5 multiple to his 12 months ended September 2019 revenue estimate, to come up with the price target of $250. Investors have historically paid 10.5 times revenue when they had positive expectations about the total addressable market opportunity for next-generation sequencing. Leonard thinks positive expectations over the next 12 months are likely, and he believes the stock is going higher.

Related Link: Illumina Now A Buy Following Q2 Beat, Improved Sales Outlook

The demand for NovaSeq could improve the results of the company going forward, said the analyst. He added that Illumina addressed all the issues for the fast NovaSeq adoption. If the NovaSeq revenue materializes in 2018 instead of in 2019, there would be a 300-bps improvement of the Wall Street’s 2018 revenue growth forecast. Leonard believes the upward revision of guidance after the second-quarter earnings results is a bullish sign. He also sees improved sales trends for the company.

Leonard believes investors are right to be concerned about market over capacity, but he thinks the demand for sequencing should grow as costs continue to fall.

Latest Ratings for ILMN

Date Firm Action From To
Oct 2017 Deutsche Bank Upgrades Hold Buy
Oct 2017 Janney Capital Upgrades Sell Neutral
Sep 2017 Argus Maintains Buy

View More Analyst Ratings for ILMN


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Upgrades Health Care Price Target Analyst Ratings Tech Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!